SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Name: SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Creator: April Armstrong
Published: 2022-10-26T11:20:27.263Z
Keywords: Clinical Trial, Skin Disease, Psoriasis

Armstrong, April

doi:10.17632/vpb6m7gmhn.2

SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Published: 26 October 2022| Version 2 | DOI: 10.17632/vpb6m7gmhn.2

Contributor:

April Armstrong

Description

Supplementary materials for the publication of Armstrong A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2022.

SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Description

Files

Categories

Licence